OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study
Marc Ferrante, Geert R. D’Haens, Vipul Jairath, et al.
The Lancet (2024) Vol. 404, Iss. 10470, pp. 2423-2436
Closed Access | Times Cited: 9
Marc Ferrante, Geert R. D’Haens, Vipul Jairath, et al.
The Lancet (2024) Vol. 404, Iss. 10470, pp. 2423-2436
Closed Access | Times Cited: 9
Showing 9 citing articles:
Understanding the therapeutic toolkit for inflammatory bowel disease
Sophie Vieujean, Vipul Jairath, Laurent Peyrin‐Biroulet, et al.
Nature Reviews Gastroenterology & Hepatology (2025)
Closed Access | Times Cited: 2
Sophie Vieujean, Vipul Jairath, Laurent Peyrin‐Biroulet, et al.
Nature Reviews Gastroenterology & Hepatology (2025)
Closed Access | Times Cited: 2
Recent advances in epidemiology, pathogenesis, diagnosis, and treatment of inflammatory bowel disease: Insights from the past two years
Jian Wan, Jiaming Zhou, Zhuo Wang, et al.
Chinese Medical Journal (2025)
Open Access | Times Cited: 1
Jian Wan, Jiaming Zhou, Zhuo Wang, et al.
Chinese Medical Journal (2025)
Open Access | Times Cited: 1
Anwendung fortgeschrittener Therapien bei chronisch-entzündlichen Darmerkrankungen
Benjamin Misselwitz, Sebastian Zeißig, Stefan Schreiber, et al.
Deleted Journal (2025)
Open Access
Benjamin Misselwitz, Sebastian Zeißig, Stefan Schreiber, et al.
Deleted Journal (2025)
Open Access
Drug Development in Inflammatory Bowel Diseases: What Is Next?
Lorenzo Petronio, Arianna Dal Buono, Roberto Gabbiadini, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 2, pp. 190-190
Open Access
Lorenzo Petronio, Arianna Dal Buono, Roberto Gabbiadini, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 2, pp. 190-190
Open Access
Role of Mirikizumab in the Treatment of Inflammatory Bowel Disease—From Bench to Bedside
Michael Colwill, Samantha Baillie, Jennifer Clough, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 3, pp. 1001-1001
Open Access
Michael Colwill, Samantha Baillie, Jennifer Clough, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 3, pp. 1001-1001
Open Access
The VIVID-1 study: A novel methodological approach provides further evidence of efficacy of selective IL-23 inhibition in Crohn’s disease
Maria Cappello, Ciro Celsa
Med (2025) Vol. 6, Iss. 2, pp. 100572-100572
Closed Access
Maria Cappello, Ciro Celsa
Med (2025) Vol. 6, Iss. 2, pp. 100572-100572
Closed Access
A patient-reported outcome measure comprising the stool frequency and abdominal pain items from the Crohn’s Disease Activity Index: psychometric evaluation in adults with Crohn’s disease
James D. Lewis, Aisha Vadhariya, Sylvia Su, et al.
Journal of Patient-Reported Outcomes (2025) Vol. 9, Iss. 1
Open Access
James D. Lewis, Aisha Vadhariya, Sylvia Su, et al.
Journal of Patient-Reported Outcomes (2025) Vol. 9, Iss. 1
Open Access
Treatment sequencing in inflammatory bowel disease : towards clinical precision medicine
Léa Sequier, Bénédicte Caron, Sailish Honap, et al.
Best Practice & Research Clinical Gastroenterology (2025), pp. 101994-101994
Closed Access
Léa Sequier, Bénédicte Caron, Sailish Honap, et al.
Best Practice & Research Clinical Gastroenterology (2025), pp. 101994-101994
Closed Access
IL23p19 therapies for moderately-to-severely active ulcerative colitis
Newaz Shubidito Ahmed, Christopher Ma
Expert Opinion on Biological Therapy (2025)
Closed Access
Newaz Shubidito Ahmed, Christopher Ma
Expert Opinion on Biological Therapy (2025)
Closed Access
Mirikizumab bei Morbus Crohn im „Treat-through-Design“ geprüft
DMW - Deutsche Medizinische Wochenschrift (2025) Vol. 150, Iss. 07, pp. 322-322
Closed Access
DMW - Deutsche Medizinische Wochenschrift (2025) Vol. 150, Iss. 07, pp. 322-322
Closed Access
Pharmacokinetic Comparability and Safety Between Original and Citrate-Free Mirikizumab Formulations for Subcutaneous Injections: Results from Three Clinical Trials
Yuki Otani, Brian G. Feagan, Geert R. D’Haens, et al.
Advances in Therapy (2025)
Open Access
Yuki Otani, Brian G. Feagan, Geert R. D’Haens, et al.
Advances in Therapy (2025)
Open Access
Expanding therapeutic options in Crohn's disease
Thomas Chapman, Jack Satsangi
The Lancet (2024)
Closed Access
Thomas Chapman, Jack Satsangi
The Lancet (2024)
Closed Access
